Evidence map›Paper›PMID 35137194›Full record

ReviewNicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco2022

Multiple Tobacco Product Use Conceptual Framework: A 2021 Update on Evidence.

Dana Rubenstein, Lauren R Pacek, F Joseph McClernon

Abstract readReview
In one paragraph

Review in Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Evaluation of Dual Use: Real Time Reductions in Combustible Cigarette Smoking During Co-Occurring Use of E-Cigarettes.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2025
    Trial
  5. Identifying Promising Message Themes for Youth Who Use Multiple Tobacco Products.The Journal of adolescent health : official publication of the Society for Adolescent Medicine · 2025
    Trial
  6. Review
  7. Article
  8. Identifying Latent Classes of Dual Cigarette/ENDS Users Based on Motivations for ENDS Use: Product Substitution Versus Complementary Use.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2026
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Effects of Very Low Nicotine Content Cigarettes and Nicotine Vaping Device Characteristics on Choices to Smoke, Vape, or Abstain in Early Young Adults.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2025
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. An Evaluation of the Contextual Factors Associated With the Use of Either Tobacco or Electronic Cigarettes in Individuals Who Dual Use.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Dana RubensteinDepartment of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC, USA.ORCID 0000-0003-4103-9641
Lauren R PacekDepartment of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC, USA.ORCID 0000-0002-1412-1765
F Joseph McClernonDepartment of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC, USA.

Funding

Impact of new standards for tobacco products among dual e-cigarette/combusted cigarette usersR01DA048454 · NIDA · DUKE UNIVERSITY · PI MCCLERNON, FRANCIS JOSEPH · 2019 to 2021
$1.4M
Mobile health interventions for varenicline adherence among HIV-positive smokersK01DA043413 · NIDA · DUKE UNIVERSITY · PI PACEK, LAUREN RENEE · 2017 to 2021
$860k
NIDA NIH HHS K01 DA043413NIDA NIH HHS R01 DA048454NIH HHS K01 DA043413
6 · The paper itself

Abstract

introductionOne-third of adults in the United States who use tobacco regularly use two or more types of tobacco products. As the use of e-cigarettes and other noncombusted tobacco products increases-making multiple tobacco product (MTP) use increasingly common-it is essential to evaluate the complex factors that affect product use. AIMS AND

methodsIn this update to our 2019 conceptual framework, we review and evaluate recent literature and expand the model to include ways in which MTP use may be affected by market factors such as the introduction of new products and socioenvironmental factors like marketing and advertising. RESULTS AND

conclusionsMTP use patterns are complex, dynamic, and multiply determined by factors at the level of individuals, products, situations or contexts, and marketplace. Substitution, or using one product with the intent of decreasing use of another, and complementarity, or using multiple products for different reasons or purposes, explain patterns in MTP use. Moreover, substitution and complementarity may inform our understanding of how market changes targeted at one product, for instance, new product standards, bans, product pricing, and taxation, affect consumption of other tobacco products. New data from natural experiments and novel laboratory-based techniques add additional data and expand the framework. IMPLICATIONS: A substantial proportion of people who use tobacco use more than one product. This review synthesizes and evaluates recent evidence on the diverse factors that affect MTP use in addition to expanding our framework. Our review is accompanied by suggested research questions that can guide future study.

Indexed as

Electronic Nicotine Delivery SystemsTobacco ProductsTobacco Use DisorderAdultHumansMarketingTobacco UseUnited States

Identifiers

PMID35137194
PMCPMC9278823

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.